Staphylococcus aureus bivalent (types 5 and 8) conjugate vaccine - Nabi

Drug Profile

Staphylococcus aureus bivalent (types 5 and 8) conjugate vaccine - Nabi

Alternative Names: S. aureus type 5 & 8 capsular polysaccharide conjugate vaccine - Nabi; Staphylococcus aureus polysaccharide conjugate vaccine bivalent - Nabi; Nabi-StaphVAX; StaphVAX-Bivalent

Latest Information Update: 26 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nabi Biopharmaceuticals; National Institutes of Health (USA)
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 31 Mar 2006 Nabi Biopharmaceuticals has resumed development of the Staphylococcus aureus vaccine conjugate following a positive review by an outside advisory panel
  • 04 Nov 2005 Nabi Biopharmaceuticals withdrawn its MAA for StaphVAX® for the prevention of Staphylococcal infections in patients with end-stage renal disease in the European Union
  • 04 Nov 2005 Clinical data from a media release have been added to the Bacterial Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top